Please use this identifier to cite or link to this item: http://ir.juit.ac.in:8080/jspui/jspui/handle/123456789/5760
Title: Comparison of Different Bio-similar for the Treatment of Auto-Immune Disorders in Europe Market
Authors: Razdan, Kumud
Hanjura, Shivani [Guided by]
Keywords: Biologics
Bioreactor
Biosimilar
Auto immune disorders
Europe market
Issue Date: 2019
Publisher: Jaypee University of Information Technology, Solan, H.P.
Abstract: There are many biologics which are somewhat same but are not exact copy of the reference product. These are often called the bio-similar. Talking about this, these have higher atomic masses and are very complex and have been dictated in a completely different manner but global health management. These are produced from only the particulates present in the living cells. The recent proposition given by the United States Food and Drug Administration (FDA) recently gave a fascinating proposition in order to praise appurtenant care drug developed by Sandoz , and also, particularly, the demoralization of biosimilars. Early biologics have given in a lot of effort to be insignificantly useful in the the treatment of serious illnesses.
Description: Dual Degree
URI: http://ir.juit.ac.in:8080/jspui//xmlui/handle/123456789/5760
Appears in Collections:Dissertations (M.Tech.)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.